CpG Enhances Immune Response to Hepatitis B Vaccine in HIV Patients
Author Information
Author(s): Angel Jonathan B, Cooper Curtis L, Clinch Jennifer, Young Charlene D, Chenier Andreane, Parato Karl G, Lautru Michael, Davis Heather, Cameron Donald W
Primary Institution: Ottawa Health Research Institute
Hypothesis
Does the addition of CpG ODN enhance the immune response to hepatitis B vaccination in HIV-infected individuals?
Conclusion
CpG 7909 enhances cellular immunity to hepatitis B vaccine antigen in HIV-infected adults.
Supporting Evidence
- The inclusion of CpG 7909 resulted in a greater proliferative response to HBsAg at all time points.
- Statistically significant increases in immune response were observed at 8 weeks and 48 weeks.
- Participants receiving CpG had a higher proportion achieving protective antibody levels compared to controls.
Takeaway
This study shows that adding a special ingredient called CpG to a hepatitis B vaccine helps the body fight the virus better, especially in people with HIV.
Methodology
A double-blind, placebo-controlled trial was conducted with HIV-seropositive individuals receiving hepatitis B vaccine with or without CpG 7909.
Potential Biases
Potential bias due to the study being funded by a pharmaceutical company involved in the research.
Limitations
The study had a relatively small sample size and focused only on specific immune responses.
Participant Demographics
Participants were HIV-seropositive adults aged 18-55, on antiretroviral therapy, with specific CD4 counts and anti-HBs titres.
Statistical Information
P-Value
0.042, 0.024
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website